Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$24.71 USD
-0.31 (-1.24%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $24.77 +0.06 (0.24%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Income Statements
Fiscal Year end for Anika Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 167 | 156 | 148 | 130 | 115 |
Cost Of Goods | 64 | 63 | 65 | 61 | 29 |
Gross Profit | 103 | 94 | 83 | 69 | 86 |
Selling & Adminstrative & Depr. & Amort Expenses | 191 | 113 | 80 | 97 | 52 |
Income After Depreciation & Amortization | -88 | -19 | 3 | -28 | 34 |
Non-Operating Income | 2 | 1 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -85 | -19 | 2 | -29 | 36 |
Income Taxes | -3 | -4 | -2 | -5 | 9 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -83 | -15 | 4 | -24 | 27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -83 | -15 | 4 | -24 | 27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | -5 | 23 | 41 | 41 |
Depreciation & Amortization (Cash Flow) | 76 | 14 | 21 | 70 | 6 |
Income After Depreciation & Amortization | -88 | -19 | 3 | -28 | 34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.66 | 14.56 | 14.63 | 14.22 | 14.37 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.49 | -0.02 | 0.71 | 2.05 |
Diluted Net EPS (GAAP) | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 |
Fiscal Year end for Anika Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 41.92 | 40.52 | 42.97 | 41.47 | 44.30 |
Cost Of Goods | 14.56 | 15.90 | 16.64 | 16.52 | 15.33 |
Gross Profit | 27.37 | 24.63 | 26.33 | 24.94 | 28.97 |
SG&A, R&D, and Dept/Amort Expenses | 27.21 | 29.69 | 27.92 | 32.62 | 32.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.16 | -5.06 | -1.59 | -7.68 | -3.63 |
Non-Operating Income | 0.60 | 0.59 | 0.58 | 0.64 | 0.56 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 0.76 | -4.47 | -63.20 | -7.04 | -3.07 |
Income Taxes | 0.84 | 0.04 | -0.20 | -0.46 | -0.33 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.09 | -4.51 | -63.00 | -6.58 | -2.74 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -0.09 | -4.51 | -63.00 | -6.58 | -2.74 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 14.84 | 14.70 | 14.65 | 14.64 | 14.69 |
Diluted EPS Before Non-Recurring Items | 0.00 | 0.09 | 0.05 | 0.00 | -0.06 |
Diluted Net EPS (GAAP) | -0.01 | -0.31 | -4.29 | -0.45 | -0.19 |